Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Innovative RTNova Platform Research, Exemplifies Pivotal Role of Research

• “Research on the treatment of cancer is fundamental to improving outcomes for all patients affected by the disease,” reports the National Cancer Institute.
• CLDI is reporting preclinical results for its systemic RTNova platform, which has successfully delivered transient gene therapy payloads to targeted tumors.
• “With this breakthrough, we can use our platform to develop multiple assets for various indications,” says CEO.

Cancer remains one of the most formidable health challenges worldwide, necessitating relentless research to uncover effective treatments. Continuous scientific inquiry has led to groundbreaking therapies, offering hope to millions. A recent development in this arena is Calidi Biotherapeutics’ (NYSE American: CLDI) announcement of promising preclinical results for its systemic RTNova platform, highlighting the critical role of research in combating cancer.

The significance of research in cancer treatment cannot be overstated. Through dedicated efforts, scientists have deepened our understanding of cancer biology, leading to the development of targeted therapies that attack specific molecular abnormalities in cancer cells. This precision medicine approach has revolutionized treatment protocols, resulting in therapies that are more effective and less harmful to healthy tissues.

“Research on the treatment of cancer is fundamental to improving outcomes for all patients affected by the disease,” states the National Cancer Institute (https://ibn.fm/LO44e). “Treatment advances, in combination with innovative diagnostic tools, are leading to therapies that are increasingly tailored to the cancer’s unique traits.”

Clinical trials are integral to translating research discoveries into clinical applications. These trials rigorously evaluate the safety and efficacy of new treatments, ensuring that only those with proven benefits reach patients. Participation in clinical trials not only provides patients with access to cutting-edge therapies but also contributes to the collective understanding of cancer treatment, paving the way for future innovations.

Calidi Biotherapeutics, a clinical-stage biotechnology company, exemplifies the fruits of rigorous research in its recent announcement (https://ibn.fm/F71fk). The company is reporting promising preclinical results for its systemic RTNova platform, which has successfully delivered transient gene-therapy payloads to targeted tumors. Additionally, Calidi’s tumor-specific virotherapy demonstrated efficacy in killing more than 60 different tumor cell lines, showcasing the platform’s potential to revolutionize cancer treatment by enabling both tumor destruction and robust immune activation.

“Targeting tumors with a systemic virotherapy with a multimodal mechanism of action, which includes direct killing of the tumors and robust activation of antitumor immune responses, may revolutionize the way we approach cancer treatments,” said a Calidi spokesman. “We are excited to have shown that our systemic platform can act also as a viral vector to express therapeutic genes in target tumors, which will maximize the potential of the designed treatment. With this breakthrough, we can use our platform to develop multiple assets for various indications, opening the door for potential partnership opportunities.”

The RTNova platform addresses significant challenges in treating advanced-stage metastatic cancers, such as lung cancer, where direct tumor injection is not feasible. Calidi has engineered a novel vaccinia virus strain enveloped with a human cell membrane, known as an extracellular enveloped virus (“EEV”). This design provides protection in the bloodstream while targeting distant tumors. Upon reaching the tumor, the virotherapy selectively replicates and destroys tumor cells, inducing an immune response that trains the immune system to recognize and target future cancer cells. Furthermore, the platform’s ability to target distant tumors allows it to act as a viral vector, delivering specific gene therapies directly to tumor sites.

Research serves as the backbone of progress in cancer treatment, leading to the development of innovative therapies that improve patient outcomes. Calidi Biotherapeutics’ recent preclinical success with the RTNova platform exemplifies how dedicated research can yield promising new treatment avenues, reinforcing the vital importance of continued investment in cancer research.

Calidi Biotherapeutics is committed to advancing the RTNova platform into clinical development, aiming to provide a novel therapeutic option for patients with metastatic cancers. The company’s mission centers on leveraging cutting-edge research to develop targeted immunotherapies that address unmet medical needs in oncology. By focusing on innovative approaches like the RTNova platform, Calidi strives to transform the landscape of cancer treatment, offering new hope to patients worldwide.

For more information, visit www.CalidiBio.com.

NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, CA
www.TinyGems.com
310.299.1717 Office